vinorelsin 50 mg/5 ml koncentrat za rastvor za infuziju
pliva d.o.o.sarajevo - винорелбин - koncentrat za rastvor za infuziju - 50 mg/5 ml - 5 ml koncentratra za rastvor za infuziju sadrži: 50 mg vinorelbina
carboplasin 450 mg/45 ml koncentrat za rastvor za infuziju
pliva d.o.o.sarajevo - karboplatin - koncentrat za rastvor za infuziju - 450 mg/45 ml - 45 ml koncentrata za rastvor za infuziju sadrži: 450 mg karboplatina
carboplasin 150 mg/15 ml koncentrat za rastvor za infuziju
pliva d.o.o.sarajevo - karboplatin - koncentrat za rastvor za infuziju - 150 mg/15 ml - 15 ml koncentrata za rastvor za infuziju sadrži: 150 mg karboplatina
carboplasin 50 mg/5 ml koncentrat za rastvor za infuziju
pliva d.o.o.sarajevo - karboplatin - koncentrat za rastvor za infuziju - 50 mg/5 ml - 5 ml koncentrata za rastvor za infuziju sadrži: 50 mg karboplatina
sinplatin 10 mg/10 ml koncentrat za rastvor za infuziju
pliva d.o.o.sarajevo - cisplatine - koncentrat za rastvor za infuziju - 10 mg/10 ml - 10 ml koncentrata za rastvor za infuziju sadrži: 10 mg cisplatina
sinplatin 50 mg/50 ml koncentrat za rastvor za infuziju
pliva d.o.o.sarajevo - cisplatine - koncentrat za rastvor za infuziju - 50 mg/50 ml - 50 ml koncentrata za rastvor za infuziju sadrži: 50 mg cisplatina
vildauno 50 mg/1 tableta tableta
pliva d.o.o.sarajevo - vildagliptin - tableta - 50 mg/1 tableta - 1 tableta sadrži: 50 mg vildagliptina
donecept 5 mg/1 tableta film tableta
pliva d.o.o.sarajevo - donepezil - film tableta - 5 mg/1 tableta - 1 film tableta sadrži: 5 mg donepezilhidrohlorid
donecept 10 mg/1 tableta film tableta
pliva d.o.o.sarajevo - donepezil - film tableta - 10 mg/1 tableta - 1 film tableta sadrži: 10 mg donepezilhidrohlorid
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. učinak иматиниба na ishod transplantacije koštane srži nije određena. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. iskustvo s иматинибом u bolesnika s mds/rafinerija u svezi s pdgfr генных permutacija-vrlo ograničen. nema kontroliranih istraživanja pokazuju kliničku korist ili povećanje preživljavanja za te bolesti.